Trials / Recruiting
RecruitingNCT07248163
Universal CAR-T Cell Therapy for NHL
A Clinical Study of the Safety and Efficacy of Universal CAR-T Cells Targeting CD19 in the Treatment of r/r B Lymphocyte Non-Hodgkin Lymphoma
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 6 (estimated)
- Sponsor
- Bioray Laboratories · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a single-center, single-arm, open-label clinical study, and the sample size is set to 3-6 subjects.
Detailed description
This is a single-center, single-arm, open-label clinical study, and the sample size is set to 3-6 subjects. Evaluating the safety, tolerability, and efficacy of BRL-301 at a dose level of 5E6/kg.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BRL-301 | The administered dose is 5×10\^6/kg |
Timeline
- Start date
- 2025-03-11
- Primary completion
- 2027-08-15
- Completion
- 2028-03-11
- First posted
- 2025-11-25
- Last updated
- 2025-11-25
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07248163. Inclusion in this directory is not an endorsement.